ARTICLE | Clinical News
Zenapax daclizumab: Began Phase II trial
December 3, 2001 8:00 AM UTC
Protein Design Labs Inc. (PDLI), Fremont, Calif. Product: Zenapax daclizumab Business: Autoimmune/Inflammation Therapeutic category: Antibody, Immune modulation Target: Alpha chain of IL-2 receptor De...